Related Experiment Video
Updated: Oct 1, 2025
Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head
Published on: September 27, 2024
The Impact of High Dose Glucocorticoids on Bone Health and Fracture Risk in Systemic Vasculitides
Christopher David Box1, Owen Cronin2,3, Barbara Hauser1,4
1Rheumatic Disease Unit, Western General Hospital, Edinburgh, United Kingdom.
Insights
Systemic vasculitis patients face increased fracture risk due to inflammation and glucocorticoid treatments. Research focuses on bone loss mechanisms and glucocorticoid-sparing therapies to mitigate osteoporosis in vasculitis.
Area of Science:
- Rheumatology
- Immunology
- Endocrinology
Background:
- Systemic vasculitides involve blood vessel inflammation, potentially affecting single organs or multiple systems.
- Treatment often requires high-dose glucocorticoids, leading to prolonged use for maintenance.
- Patients with vasculitis have a higher risk of fractures and osteoporosis.
Purpose of the Study:
- To review the mechanisms of bone loss in vasculitis.
- To summarize fracture risk factors in different vasculitis types.
- To discuss osteoporosis treatment considerations for vasculitis patients.
Main Methods:
- Literature review on bone loss mechanisms in vasculitis.
- Analysis of fracture risk factors associated with vasculitis and its treatments.
- Discussion of current and emerging osteoporosis management strategies.
Main Results:
- Osteoporosis in vasculitis stems from chronic inflammation, renal dysfunction, and particularly glucocorticoid therapy.
- Fracture risk is elevated in both small and large vessel vasculitis.
- Glucocorticoid-sparing agents are crucial for reducing cumulative steroid doses and associated fracture risk.
Conclusions:
- Understanding bone loss mechanisms is key to managing osteoporosis in vasculitis.
- Reducing glucocorticoid exposure through alternative immunosuppressants is a primary therapeutic goal.
- Further research is needed to fully elucidate the relationship between vasculitis, its treatment, and bone health.
Abstract:
Systemic vasculitides are a range of conditions characterized by inflammation of blood vessels which may manifest as single organ or life-threatening multisystem disease. The treatment of systemic vasculitis varies depending on the specific disease but historically has involved initial treatment with high dose glucocorticoids alone or in conjunction with other immunosuppressive agents. Prolonged glucocorticoid treatment is frequently required as maintenance treatment. Patients with small and large vessel vasculitis are at increased risk of fracture. Osteoporosis may occur due to intrinsic factors such as chronic inflammation, impaired renal function and to a large extent due to pharmacological therapy with high dose glucocorticoid or combination treatments. This review will outline the known mechanism of bone loss in vasculitis and will summarize factors attributing to fracture risk in different types of vasculitis. Osteoporosis treatment with specific consideration for patients with vasculitis will be discussed. The use of glucocorticoid sparing immunosuppressive agents in the treatment of systemic vasculitis is a significant area of ongoing research. Adjunctive treatments are used to reduce cumulative doses of glucocorticoids and therefore may significantly decrease the associated fracture risk in patients with vasculitis. Lastly, we will highlight the many unknowns in the relation between systemic vasculitis, its treatment and bone health and will outline key research priorities for this field.
More Related Videos
07:38Adult Zebrafish Injury Models to Study the Effects of Prednisolone in Regenerating Bone Tissue
Published on: October 18, 2018
06:35An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:25Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:27Fractures: Bone Repair
Minor fractures with no bone displacement are treated by immobilizing the fractured bone using a cast or splint. However, in the case of fractures with displaced bones, the broken bones are repositioned before immobilization to ensure successful healing without deformation and loss of function. The realignment of fractured bone ends is performed through a process called reduction. If the...
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...